Advanced Accelerator Applications
Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology indications. We are committed to transforming patients’ lives by leading innovation in nuclear medicine.
Founded in 2002, AAA has a legacy as a pioneer in the development and delivery of radiopharmaceutical drugs for diagnostic imaging. More recently, AAA has focused its efforts on developing targeted radioligand therapies and precision imaging diagnostics that target specific markers that are over-expressed by certain types of solid tumors. AAA currently employs more than 1,100 associates across 31 sites in 12 countries; with 19 manufacturing facilities in 8 countries and 6 research and development sites.
An overview of the AAA pipeline for targeted radioligand therapy and precision imaging.
Pocket PSMA: Explore the Science of Targeted Radioligands.
PSMA in Prostate Cancer
Learn about the role of PSMA in precision medicine for prostate cancer.